Replimune REPL
NASDAQ REPL
$23.28 +1.02 (+4.58%)
At close: Nov 10, 2026 · 4:00 PM EST

Replimune (REPL) EBITDA Margin (2017 - 2018)

Updated

Replimune (REPL) posted EBITDA Margin of -1145.12% for fiscal Q3 2019 (quarter ended Dec 31, 2018), up 13545.50 percentage points from -14690.63% a year earlier but down 80.67 percentage points from the prior quarter.

Analysis

Replimune (REPL) EBITDA Margin (2017 - 2018) Analysis & Trends

For the trailing twelve months through Dec 31, 2018, EBITDA Margin at Replimune was -1664.88%.

  • Quarterly EBITDA Margin has run from a low of -42290.00% in fiscal Q2 2018 to a high of -1064.46% in fiscal Q2 2019 over five years.
  • On a year-over-year basis, EBITDA Margin has increased in each of the last three quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 54.65%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 32.68%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 46.88%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 40.75%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 46.62%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 50.63%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 42.49%
10 Replimune 2.40 Bn 1.35 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -1,145.12%
Sep 30, 2018 -1,064.46%
Jun 30, 2018 -2,575.33%
Dec 31, 2017 -14,690.63%
Sep 30, 2017 -42,290.00%
Jun 30, 2017 -10,510.00%
API Access

Replimune EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY